News from ASCO 2019

Blueprint Medicines announced data from their registration-enabling NAVIGATOR trial of avapritinib in patients with PDGFRA Exon 18 mutant GIST and fourth-line GIST.


These results were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting and will form the basis for planned worldwide marketing applications for avapritinib. The data demonstrate clinical activity and favourable tolerability in patients with PDGFRA Exon 18 mutant and fourth-line GIST, two populations with no effective therapies. 

Please see the press release here.

Posted in GIST News.